Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action.
Morris
R E
RE
Department of Cardiothoracic Surgery, Stanford University School of Medicine, California 94305-5247.
D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D011090:Polyenes / Q000494:pharmacology / Q000627:therapeutic use*; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D011090:Polyenes; D020123:Sirolimus